Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morschhauser

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|June 3, 1999
Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL)I Leclercq, F Mortreux, F Morschhauser, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 15, 2015
Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to RituximabJ Rossignol, L Terriou, D Robu, et al.
Annales De Dermatologie Et De Venereologie|May 7, 2008
[Intravascular lymphoma revealed by generalized arborescent telangiectasia and repeated venous thrombosis]S Vercambre-Darras, L Mortier, M Lambert, et al.
Scientific Reports|October 7, 2018
A new pharmacokinetic model for <sup>90</sup>Y-ibritumomab tiuxetan based on 3-dimensional dosimetryF Morschhauser, B Dekyndt, C Baillet, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 21, 2018
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluidD Beauvais, J-F Goossens, E Boyle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2006
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphomaF Morschhauser, S Depil, E Jourdan, et al.
Leukemia|January 28, 2005
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)H Leroy, S de Botton, N Grardel-Duflos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2010
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric studyE Lopci, I Santi, E Derenzini, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Assessing the Cox model assumption as a statistical tool for classifying lymphomasP Morel, B Souleau, F Morschhauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2010
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphomaF Morschhauser, P Marlton, U Vitolo, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|June 3, 1999
Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL)I Leclercq, F Mortreux, F Morschhauser, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 15, 2015
Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to RituximabJ Rossignol, L Terriou, D Robu, et al.
Annales De Dermatologie Et De Venereologie|May 7, 2008
[Intravascular lymphoma revealed by generalized arborescent telangiectasia and repeated venous thrombosis]S Vercambre-Darras, L Mortier, M Lambert, et al.
Scientific Reports|October 7, 2018
A new pharmacokinetic model for <sup>90</sup>Y-ibritumomab tiuxetan based on 3-dimensional dosimetryF Morschhauser, B Dekyndt, C Baillet, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 21, 2018
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluidD Beauvais, J-F Goossens, E Boyle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2006
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphomaF Morschhauser, S Depil, E Jourdan, et al.
Leukemia|January 28, 2005
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)H Leroy, S de Botton, N Grardel-Duflos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2010
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric studyE Lopci, I Santi, E Derenzini, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Assessing the Cox model assumption as a statistical tool for classifying lymphomasP Morel, B Souleau, F Morschhauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2010
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphomaF Morschhauser, P Marlton, U Vitolo, et al.
Pageof 5